KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

2025 9TH KAPAL ANNUAL CONFERENCE

with Adelphi Ventures, JHBIC, KIC-DC, and KLAM

" HARMONY AND INNOVATION "

OCT | 24th - 25th | 2025

Gaithersburg Marriott Washingtonian Center

KHIDI 한국보건산업진흥원 Korea Health Industry Development Institute

MEDICAL KOREA Where your days begin again

대한민국

KLAM Korean Life scientist Association of Maryland 메릴랜드 한인 생명과학자 협회

KIC Korea Innovation Center Washington DC

ADELPHI VENTURES

JOHNS HOPKINS UNIVERSITY

Global Biotechnology Innovation Center

SAMSUNG BIOEPIS

At Samsung Bioepis

We use innovative science and technology to find smarter, faster ways of getting quality-assured medicines to the people who need them most. We have 11 biosimiliars approved and 11 launched successfully in more than 40 countries, helping to improve the lives of patients through increased accessibility to medicines.

We are teaming up with biotech companies to research and develop new Antibody-Drug Conjugate (ADC) and gene therapy technologies with the help of the Samsung Life Science Fund.



PASSION for HEALTH

Biostar Nature Cell

Since 2001, Biostar has dedicated to R&D of mesenchymal stem cells (MSCs) derived from patients' own adipose tissue. To enable the clinical application of MSCs in humans, Biostar has developed highly safe and effective stem cell culture technologies. Since 2006, the company has preserved stem cells from **19,346** individuals, establishing the world's largest adipose stem cell bank, and has accumulated over **32,800** clinical cases, making it the global leader in stem cell treatment experience. By implementing a pharmaceutical-grade GMP system that exceeds the standards of regenerative medicine, Biostar has strengthened the manufacturing and quality control of its stem cell products. The company has successfully developed stem cell based templates.

JointStem is the globally first clinical stage stem cell therapy for knee osteoarthritis, and became the first Korean pharmaceutical company to receive both **Regenerative Medicine Advanced Therapy** and **Breakthrough Therapy** designations from the U.S. FDA. With a fully integrated "bench-to-bedside" system, Biostar is pioneering the global field of regenerative medicine committed to extending and enhancing the youthful and healthy lives of humankind.

The company is currently establishing the Biostar Stemcell Campus in **Baltimore**, which will enable the annual production of one million doses of JointStem. In addition, Biostar plans to launch state-level regenerative therapies in the United States, beginning in **Florida**, to provide treatment for American patients.



WELCOME MESSAGE

Dear KAC 2025 Participants,

As the 3rd President of the Korean American Professional Association in Life Sciences (KAPAL), it is my great honor to host the 9th KAPAL Annual Conference and the Joint Symposium with Adelphi Ventures, the Johns Hopkins Global Biotechnology Innovation Center (JHBIC), the Korea Innovation Center Washington DC (KIC-DC), and the Korean Life Scientists Association of Maryland (KLAM).

It is truly a pleasure to welcome you all here today. Thank you for taking the time out of your busy schedules to join us. This symposium has been made possible through the dedication and hard work of so many people who have given their time and energy, often late into the night. While I cannot name everyone individually, I want to extend my heartfelt gratitude to each of you. I would also like to express my sincere appreciation to the Embassy of the Republic of Korea in the United States, the Korea Health Industry Development Institute (KHIDI), the State of Maryland, and our corporate sponsors for their generous support.

Looking back, 2025 has been a challenging year for many of us. Across Korea, the United States, and the world, shifts in policy, a tightening investment climate, and many unpredictable variables have created difficulties for the life sciences community. And yet, despite these challenges, Korean startups have achieved remarkable progress in life sciences and other industries, while the United States continues to lead the global biopharmaceutical sector with great vitality. Each of you present today is a living testament to these achievements.

The theme of this year's symposium is "Harmony and Innovation." We believe that in times of uncertainty, the most powerful path forward lies in learning from one another, working together, and creating new opportunities. Over the next two days, we hope that experts from diverse fields (basic research, clinical studies, drug development, business development, intellectual property, and investment) will engage in meaningful conversations and build a new culture of collaboration.

Just as Korea's cultural and food industries have made a powerful impact worldwide, I am confident that in 2026 the life sciences industry will once again make waves on the global stage. We, too, will continue to stand with you on this journey, and we promise to bring more opportunities and programs to strengthen our collective efforts.

Finally, I would like to once again thank each and every one of you for being here today. Please take a moment to greet those around you warmly, and let us make these coming days not only fruitful but also inspiring.

Thank you.

Jihoon Park, President of KAPAL

KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

JOINT ORGANIZING COMMITTEE CHAIRS

Jihoon Park
President
KAPAL

Tae Heum Jeong
Managing Partner
Adelphi Ventures

Deok-Ho Kim
Professor
JHU

Hyungjin Yun
Sr. Manager
KIC-DC

Su-Jeong Kim
Research Associate
JHU, KLAM

Hyun Jong Kim
President
KAPAL (CA)

JOINT ORGANIZING COMMITTEE

KAPAL

Han-sol Park
Vice President

Eunjung Choi
Admin Dir.

Byung Ha Lee
Exec. Dir.

Sang Tae Park
Exec. Dir.

Suntae Kim
IT Dir.



Young O Hahm
BD Dir.



Eunkyung An
Exec. Dir.

Woosub Lee
General Dir.

Sung Park
Program Dir.

Bumrae Cho
Program Dir.

Juny Kim
Public Affairs Dir.

Justin Lee
General Dir.

Adelphi Ventures

David Kim
Partner

KIC-DC

Chang Hee Kim
President

Songhee Han
Senior Mgr.

Sewon Lee
Program Mgr.

Sanghyun Park
Program Mgr.

JHBIC

Hyeoncheol Park
Assoc Dir.

Boyoung Cha
Sr. Program Coord.

Nathan Byun
Program Mgr.

KAPAL

KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

2025 9th KAPAL Annual Conference

FRI | OCT.24.2025 | 9AM-9PM **SALONS D-G**

Start	Session	Speaker
8:00 AM – 9:30 AM	*Online Session – Siyeon Rhee, PhD, Stanford*	*Note: This session will be available online only.*
9:00 AM	Registration & Networking	
JHBIC: JHU-Korea Biotechnology Innovation Symposium		
9:30 AM	Opening Remark	Deok-Ho Kim, PhD, Professor, JHU
9:35 AM	Korea-US Industrial Technology Cooperation	Hwan Il Yoo, PhD, US Director, KIAT
9:45 AM	Johns Hopkins Global Biotechnology Innovation Center: Pioneering Biotechnology and Healthcare Through Academic-Industry Partnerships Across US-Korea Borders	Hyeoncheol Park, PhD, Research Associate, JHU; Associate Director, JHBIC
10:00 AM	Sponsor Talk: Nature Cell Co., Ltd.	Sang Mok Chung, PhD, President, Stemcell Bio
10:20 AM	AI-Optical Image-Guided Robotic Surgeries	Jin U Kang, PhD, Jacob Suter Jammer Professor, JHU
10:35 AM	**Group Photo & BREAK**	
10:45 AM	Enabling Innovation through Partnerships.	Dushon Riley, PhD, Director Business Development, JHTV
11:00 AM	Designing medical devices with computational biophotonics	Nicholas Durr, PhD, Associate Professor, JHU
11:15 AM	Sponsor Talk: Kolon TissueGene, Inc.	Huan Tran, PhD, Head of Discovery, Kolon TissueGene, Inc.
11:35 AM	Sponsor Talk: Celloid Co., Ltd.	Donghyeon Lee, CTO, Celloid Co., Ltd.
11:45 AM	TEDCO Introduction	Troy LeMaile-Stovall, CEO, TEDCO
12:00 PM	**LUNCH**	

2025 9th KAPAL Annual Conference

FRI | OCT.24.2025 | 9AM-9PM **SALONS D-G**

Start	Session	Speaker
	KIC-DC: KIC-DC Tech Summit	
1:00 PM	Opening and Welcome	• Changhee Kim, President, KIC-DC • Yeon Hak Kim, Science & ICT Attache, Embassy of the Republic of Korea
1:10 PM	Pitching Competition Group #1	
1:40 PM	Panel Presentation - Company Intros	• Bumsoo Kim, Managing Partner, Quantum Prime Ventures • Hyukmin Kwon, PhD, Senior Principal, Entegris Ventures • Rhie Lim, Venture Partner, One Way Ventures
2:05 PM	*Moderator: Bumsoo Kim (Managing Partner, Quantum Prime Ventures)* Tech Sector Investment perspectives Panel Discussion Topic: Blind Spots in the Founder's Journey: What VCs Really Wish You Knew	• Troy A. LeMaile-Stovall, CEO, TEDCO • Hyukmin Kwon, PhD, Senior Principal, Entegris Ventures • Rhie Lim, Venture Partner, One Way Ventures
2:35 PM	**BREAK**	
2:55 PM	Pitching Competition Group #2	
3:25 PM	Panel Presentation • Redefining Early-Stage Biotech: Curie.Bio's Model for Seed Investment and Drug-Discovery Copiloting • The Resurgence of the Biotech Sector • How US Venture Capital Firms Evaluate Companies in the AI Era	• Patrick Lee, PhD, Vice President, Curie.Bio • Elizabeth Cho-Fertikh, PhD, Managing Partner, MEDA Ventures • Deborah Hemingway, PhD, Managing Partner, Ecphora Capital
4:10 PM	*Moderator: Tae Heum Jeong (Managing Partner, Adelphi Ventures)* Biotech Sector Investment perspectives Panel Discussion Topic: Bridging Intelligence and Biology: AI-Driven Innovation in Biotech	• Patrick Lee, PhD, Vice President, Curie.Bio • Deborah Hemingway, PhD, Managing Partner, Ecphora Capital • Elizabeth Cho-Fertikh, PhD, Managing Partner, MEDA Ventures
4:40 PM	Announcement of the Finalists	
4:50 PM	An introduction to KOTRA	Rachel Jayeon Shim, General Affairs Manager, KOTRA Washington DC
5:00 PM	**DINNER & NETWORKING (Continue Registration)**	

2025 9th KAPAL Annual Conference

FRI | OCT.24.2025 | 9AM-9PM **SALONS D-G**

Start	Session	Speaker
KAPAL Annual Conference		
6:30 PM	*Moderator: Jihoon Park (President, KAPAL)* Welcome Remarks & Group Photo	• Jihoon Park, PhD, President, KAPAL • Seung Hyun Moon, MD, Venture Partner, Adelphi Ventures • Chung-Hwan Kim, Minister Counselor for Health • Soonmahn Park, PhD, President, KHIDI USA • Richard Madaleno, Chief Administrative Officer, Montgomery County, MD • Susan Lee, State of Maryland
7:00 PM	Keynote Lecture: The Role of Philanthropy in Catalyzing Research and Innovation	Michael W. Nestor, PhD, Board of Director, The National Academies of Sciences, Engineering, and Medicine
7:40 PM	Company Talk 1_SK Life Science, Inc.	Keunyong Austin Cho, MBA, Vice President of Commercial, SK Life Science, Inc.
8:00 PM	Company Talk 2_Samsung Bioepis Co., Ltd.	KyoungSoo Lim, MD, PhD, Vice President of Translational Medicine, Samsung Bioepis Co., Ltd.
8:20 PM	Pitching Competition- Final	5 Finalists
8:50 PM	**Ceremony**	
9:10 PM - 10:30 PM	*Networking (with light snacks and drinks)*	

2025 9th KAPAL Annual Conference

SAT | OCT.25.2025 | 9AM-8PM **SALONS A-E**

Start	Session	Speaker
8:00 AM	**Breakfast and Networking**	
9:00 AM	Opening the 2nd Day	Jihoon Park, PhD, President, KAPAL
	Moderator: HJ Kim (President, KAPAL-CA)	
9:10 AM	Commercializing Your Innovation- Medicare Coverage and Payment Considerations for MedTech	• Jongho "Phillip" Won, PhD, Senior Associate, Alston & Bird, LLP. • Brian Lee, Partner, Alston & Bird, LLP.
10:10 AM	Introduction of KAPAL - CA	Hyun Jong Kim, President, KAPAL CA
10:20 AM	Navigating the IRB submission process in accordance with FDA submission	Lauren Hartsmith, JD, CIP, Advisor, BRANY IRB
10:45 AM	Panel discussion: Strategies for Leveraging Incubators and Regional Innovation Ecosystems: From Startup to Investment and Growth	• Dr. David Kiewlich, PhD, Tomorrow Biotech • Donald P. Taylor, PhD, MBA, CLP, UC Davis Health Ventures
11:30 AM	Investment Market- Viewpoint from the investors	Sougato Das, President, Life Science Nation
12:00 PM	LUNCH & Breakout Sessions: Meet with Venture Capitalists (VC) • Biotech: Patrick Lee, PhD (Vice President, Curie.Bio) • MedTech: Deborah Hemingway, PhD (Managing Partner, Ecphora Capital) • Angel/Seed: Elizabeth Cho-Fertikh, PhD (Managing Partner, MEDA Ventures) • Cross-Border: Tae Heum Jeong (Managing Partner, Adelphi Ventures) • BD: Jung Lee (Venture Partner, Adelphi Ventures) • Clinical/Commercilization: Seung Hyun Moon, MD (Venture Partner, Adelphi Ventures)	
	Moderator: Jihoon Park (President, KAPAL)	
1:20 PM	Company Talk 3_Yuhan USA Co., Ltd.	Taewon Yoon, PhD, CEO, Yuhan USA Co., Ltd.
1:25 PM	Company Talk 4_Huonslab Co., Ltd.	ByungHa Lee, PhD, CBO, Huonslab, Co., Ltd.
1:30 PM	Company Talk 5_ABLE labs, Inc.	Jeong-woo Oh, PhD, Senior Research Scientist, ABLE labs, Inc.
1:35 PM	Updates in the Digital Health World and Their Implications	Sungwon Park, Partner, Reed Smith
2:05 PM	Current Status of the Council of Advanced Regenerative Medicine (CARM) in Korea Cell and Gene Therapy Industry	Kyung-Sun Kang, Professor, Seoul National University, Former President of CARM
2:35 PM	K-BB Center: A Boston Gateway for Translational R&D and Venture Partnerships	Eun Gyeong Yang, PhD, Director, K-BB Center Planning Group, KIST

2025 9th KAPAL Annual Conference

SAT | OCT.25.2025 | 9AM-8PM **SALONS A-E**

Start	Session	Speaker
3:05 PM	**BREAK**	
	Moderator: SJ Kim (President, KLAM)	
3:25 PM	Epigenetic control of topoisomerase 1 activity presents a cancer vulnerability	Tae-Hee Lee, PhD, Postdoctoral Fellow Radiation Oncology & Molecular Radiation Sciences, JHU
3:45 PM	Cell type-specific barcoding reveals the projectional architecture of the mouse midbrain dopaminergic system	Hyopil Kim, PhD, Postdoctoral Fellow Department of Biomedical Engineering, JHU
4:05 PM	Nanotubular Network in the Brain: A New Dimension of Neuronal Connectivity beyond Synapses	Minhyeok Chang, Ph.D. Research Associate, Neuroscience, JHU
4:25 PM	Keynote Lecture: Brain as a Reinforcement Learning Machine	Daeyeol Lee, PhD, Bloomberg Distinguished Professor of Neuroscience, Department of Neuroscience, Johns Hopkins University
5:05 PM	Closing Ceremony	Heemin Rhee, PhD.
5:25 PM -7:25 PM	**DINNER & NETWORKING**	

Career Development Session *(Parallel Session | **Salon A**)* **Saturday, Oct 25 | 9:00 – 10:30 AM**		
9:00 AM	Resume Writing and Interview Tips	SK Biopharm
9:40 AM	Q&A and Group Discussion	Seniors from public, private, and academic sectors
10:20 AM	Professional Photo Booth Open	Professional Photographer

2025 KAPAL Annual Conference

KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

SK biopharmaceuticals
YUHAN USA
Humanizing Phenomics 120 psomagen

JOIN US FOR A
CAREER DEVELOPMENT SESSION

October 25 | 9-11 AM

- Resume Writing, Interview Tips by SK Biopharmaceuticals
- Panel Discussion
- Profile Photo

WE'RE HIRING

YUHAN USA

- Business Development Manager

- Laboratory Technician
- Junior Bioinformatics Scientist
- Marketing Specialist
- Senior Bioinformatics Scientist
- Accounting Staff
- Senior NGS Project Manager

Humanizing Phenomics 120 psomagen

Please send an e-mail for more information:
hansolpark@kapal.org and sjkimtina@gmail.com



SPEAKERS

KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

2025 9TH ANNUAL CONFERENCE



DAY 1 - JHBIC

Deok-Ho Kim, Ph.D.

Professor, JHU

Bio: Dr. Deok-Ho Kim is a Professor of Biomedical Engineering and Medicine, as well as the founding Director of the Center for Microphysiological Systems at The Johns Hopkins University. Previously, he held a tenured Associate Professorship in the Department of Bioengineering at the University of Washington, Seattle (2011-2019), and worked as a Research Scientist at the Korea Institute of Science and Technology (KIST), including an academic visit to the Swiss Federal Institute of Technology at Zurich (ETH-Zurich) (2000-2005). He earned his B.S. in Mechanical Engineering from POSTECH, Master's in Mechanical Engineering from Seoul National University, and Ph.D. in Biomedical Engineering from Johns Hopkins School of Medicine in 2010. Dr. Kim's research focuses on developing advanced biomaterials/devices and stem cell/tissue engineering technologies for disease modeling, drug development, and regenerative medicine. He has published over 200 peer-reviewed papers, 2 books, and 11 book chapters. His papers have been cited over 20,000 times (H-index: 74) and have been highlighted in Science Magazine, the JHU Gazette, UW Today, CNN, and various newspapers. He is an elected Fellow of the American Institute for Medical and Biological Engineering, the Royal Society of Chemistry, the American Heart Association, and the Society for Laboratory Automation and Screening. His innovative work at the intersection of biological, physical, and engineering sciences for medicine has been recognized by numerous honors, including the Samsung Humantech Thesis Award, the Harold M. Weintraub Award in Biological Science, the American Heart Association National Scientist Development Award, the Young Innovator Award of Cellular and Molecular Bioengineering from the Biomedical Engineering Society, the IEEE NANOMED Innovator Award, the Mid-Career Award from International Society of Biofabrication (ISBF), and the KSEA Engineer of the Year Award from the Korean Federation of Science and Technology Societies. He has filed over 40 patents, many of which have been licensed for commercialization. In 2015, he founded a biotech startup company, Curi Bio Inc., which integrates advanced 3D tissue models of human disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights. Curi Bio received the 2020 Tibbetts Award by the US Small Business Administration and the 2021 Edison Award. He currently serves on the scientific advisory board for several companies including Samsung Biologics, Samsung Bioepis, Vita Therapeutics, and Curi Bio. Additionally, he currently serves as the President of Korean-American Biomedical Engineering Society, and as a founding Director of the JHU-Korea Global Biotechnology Innovation Center sponsored by the South Korean Ministry of Trade, Industry and Energy.

Hwan il Yoo

US Director, KIAT

Bio: Hwan il Yoo directs the Korea Institute for Advancement of Technology (KIAT) US Office from Vienna, Virginia, where he serves as KIAT's principal representative for Korea-US industrial technology cooperation.
Mr. Yoo serves as a catalyst for innovation by connecting researchers and scientists, entrepreneurs, innovators, and policy makers to advance industrial technology development. As a representative of one of Korea's most influential industrial technology organizations, he cultivates sustainable partnerships that strengthen the research and innovation ecosystem between Korean and American institutions.

Summary

The presentation will cover how the KIAT US Office orchestrates joint research initiatives through the Global Industrial Technology Cooperation Center (GITCC) program, which focuses on 100 next-generation technologies.
Mr. Yoo will discuss his comprehensive oversight of bilateral R&D collaboration programs spanning critical technology sectors, including artificial intelligence, semiconductors, biotechnology, and advanced manufacturing, and under his strategic leadership, the discussion will also highlight his leadership of the Korea Technology Advisory Group (K-TAG), an extensive network of Korean scientists and experts across the United States who provide R&D mentoring and partnership facilitation services to Korean companies seeking international collaboration.

DAY 1 - JHBIC

HyeonCheol Park, Ph.D.

Research Associate, JHU; Associate Director, JHBIC

Title: Johns Hopkins Global Biotechnology Innovation Center: Pioneering Biotechnology and Healthcare Through Academic-Industry Partnerships Across US-Korea Borders

Summary
The Johns Hopkins Global Biotechnology Innovation Center (JHBIC) is a pioneering hub dedicated to advancing biotechnology and healthcare research and development, with a focus on technology commercialization. JHBIC's mission is to accelerate innovation in biotechnology and drug discovery by providing tailored R&D support, technology incubation, and strategic consulting services. Designed to foster collaboration between Johns Hopkins University (JHU) and Korean companies, JBIC leverages JHU's renowned expertise in biomedical engineering, pharmaceuticals, and AI/digital healthcare to offer a versatile platform for joint research, technology transfer, and commercialization. The Center provides Korean partners access to state-of-the-art laboratories, core facilities, and dedicated incubation spaces. Strategically located near key U.S. regulatory and research institutions, JBIC is uniquely positioned to support Korean companies in entering the U.S. market. By promoting cross-border collaboration, JHBIC aims to catalyze groundbreaking research and create an ecosystem for global biotechnology innovation and commercialization.

Sang Mok Chung, Ph.D.

President, Stemcell Bio

Title: JointStem and US Development Plans

Bio: Dr. Chung is the president of Stemcell Bio, responsible for building the global clinical and regulatory registration strategies of regenerative therapeutics development at Biostar. Biostar is a global leader in regenerative therapeutics as the company has provided stem cell therapeutics for up to 16 approved indications under Japan's Regenerative Medicine Promotion Act and two commercial INDs indicating for serious knee osteoarthritis and Alzheimer's Disease in US. Further, Biostar has provided stem cell banking services.
Dr. Chung has over 25 years' experiences at full breadth of new medicinal product development covering broad range of therapeutic areas and molecular platforms. Dr. Chung's leadership and portfolio management have been uniquely evolved from hands-on experiences at both health authorities and industry sectors. Dr. Chung earned Ph.D. in Pharmacokinetics from the College of Pharmacy, University of Illinois at Chicago.

Dushon Riley, Ph.D.

Director Business Development, JHTV

Bio: Dushon is the Director of Corporate Partnerships and Business Development for the Whiting School of Engineering within Johns Hopkins Technology Ventures (JHTV), the commercialization office for Johns Hopkins University. His responsibilities include independently sourcing, cultivating, and managing strategic industry partnerships that align seamlessly with the cutting-edge research and educational activities within the Johns Hopkins Whiting School of Engineering.
Dushon earned his B.A. in Neuroscience from Johns Hopkins University. He earned his Ph.D. in Cardiac Physiology from the University of Maryland Baltimore and completed postdoctoral fellowships at the University of Maryland Biotechnology Institute and the US Food and Drug Administration.
During his talk, JHTV: Enabling Commercialization of Innovation at Hopkins, Dushon will discuss how JHTV serves as a front door for campus innovators and external partners alike, ensuring productive collaboration between Johns Hopkins and its partners to bring the benefits of academic discovery to the world.

DAY 1 - JHBIC

Jin U. Kang, Ph.D.

Jacob Suter Jammer Professor, JHU

Bio: Jin U. Kang is the Jacob Suter Jammer Endowed Chair Professor in the Department of Electrical and Computer Engineering and a Professor in the Department of Dermatology at Johns Hopkins University, where he joined as an Assistant Professor in 1998. His research focuses on developing novel optical techniques and devices for a broad range of biomedical applications. He has served as General Chair of CLEO and as a program committee member of the SPIE Biosensing group. He is a Fellow of OSA, SPIE, and AIMBE, and has served as a topical editor for Optics Letters and as an editorial board member for Chinese Optics Letters and the Optical Society of Korea. He received his Ph.D. in Optical Sciences/Electrical Engineering from the College of Optics & Photonics at the University of Central Florida in 1996.

Abstract
Recent advances in optical imaging and artificial intelligence are driving the development of the next generation of robotic surgical devices and systems. In this intelligent surgical platform, optical sensors and advanced neural networks are seamlessly integrated with robotic tools to achieve outcomes beyond the limits of freehand human performance. At Johns Hopkins, our laboratory has been developing real-time 3D imaging systems tailored for robotic microsurgery. These systems enhance the surgeon's ability to visualize optically transparent tissues, identify and track nearly invisible tissue edges, maintain safe operating positions, detect early instrument–tissue contact, and assess depth of penetration with micron-level precision. Collectively, these innovations reduce surgical risk, improve safety, and expand the scope of achievable surgical objectives. In this talk, I will summarize our progress in optical image–guided robotic surgery and outline future directions for this rapidly evolving field.

Nicholas J. Durr, Ph.D.

Associate Professor, JHU

Title: Designing medical devices with computational biophotonics

Bio: Nicholas Durr is an Associate Professor of Biomedical Engineering at Johns Hopkins University with appointments in the Center for Bioengineering Innovation & Design, Electrical & Computer Engineering, and Ophthalmology. He directs the Computational Biophotonics Lab and teaches the capstone undergraduate medical device design program. He received a B.S. in Electrical Engineering and Computer Science from UC Berkeley in 2003 and a Ph.D. in Biomedical Engineering from UT Austin in 2010. He was an M+Visión Fellow at MIT from 2011 to 2014. In 2013 he co-founded PlenOptika, which he led as CEO until he joined Hopkins in 2016.

Abstract:
Computational biophotonics pairs optical system design with the development of intelligent algorithms to extract meaningful data from interrogated tissues (often via an unintuitive computational image). With the recent advances in deep learning, there are many exciting opportunities to jointly design data-driven models with novel optical imaging systems to create impactful medical devices. I will present our research in developing and translating computational biophotonics technologies for a variety of important healthcare needs, including: (1) enabling a non-invasive complete blood count with oblique back-illumination capillaroscopy, (2) preventing colorectal cancer with a computational colonoscope, (3) enabling through-catheter infection screening with lens free holographic microscopy, and (4) increasing access to eye care in low-resource settings with a low-cost, handheld wavefront aberrometer.

DAY 1 - JHBIC

Huan Tran

Head of Discovery, Kolon TissueGene

Title: TissueGene-C, A Potential Therapeutic for Treating Degenerative Joint Diseases

Huan T. Tran[1]
[1] KOLON TissueGene, Inc., Rockville, MD, United States.

TissueGene-C (TG-C) is a novel cell-based gene therapy combination consisting of human allogeneic chondrocytes and irradiated/transduced mammalian cell line expressing TGF-β1. Clinical studies results showed TG-C provides significant improvements in pain and function for patients with knee osteoarthritis (OA) in both US Phase 1 and 2 trials. Animal studies demonstrated that TG-C can reduce pain and improve cartilage structure of the knee joints via stimulating M2 macrophages recruitment and polarization in rat OA model. Additional followed-up studies confirmed TG-C induces anti-inflammatory activity in M2 macrophages polarization in in-vitro macrophages derived cell model. Our results demonstrate that prostaglandin E2 (PGE_2) was identified as the key bioactive factor(s) responsible for the recruitment of M2 macrophages polarization and inducing anti-inflammatory response of TG-C.In addition to knee OA, TG-C shows promise for treating other degenerative joint conditions. In the rat DDD model, TG-C treatment led to a significant pain reduction starting at 1-week and maintained through 4-week after cells administration. Taking together, these findings support TG-C as a viable and effective therapy for treating degenerative joint diseases.

Donghyeon Lee, Ph.D.

CTO, Celloid.

Title: Automated 3D Cell Culture Platforms for Scalable and Reproducible Organoid Production

Bio: Donghyeon Lee is a CTO of Celloid Co., Ltd. He received his B.S., M.S., and Ph.D. degrees in Mechanical Engineering from POSTECH, with a research focus on robotics and control theory. His research has been published in leading robotics journals, including IEEE Transactions on Robotics and IEEE/ASME Transactions on Mechatronics. After joining Celloid Co., Ltd., he has focused on developing automated systems for 3D cell culture, particularly organoid applications. Most recently, he led the development and launch of OrgaNest® Basic Plus, an automated platform that allows organoid culture with high reproducibility and efficiency.

Abstract: Engineering physiologically relevant microenvironments is critical for advancing organoid research in tissue engineering and regenerative medicine. Despite recent progress, challenges remain in achieving reproducibility, scalability, and biological relevance of organoids. To address this, we introduce NestWell®, a permeable microwell platform with a 3D geometrically engineered nanofibrous membrane that enables precise control of organoid size and ensures unconstrained delivery of nutrients and differentiation signals. In parallel, OrgaNest®, an automated culture system, enhances reproducibility, reduces culture costs while supporting scalable organoid production.

DAY 1 - JHBIC

Troy LeMaile-Stovall

CEO, TEDCO

Bio: Troy A. LeMaile-Stovall currently serves as CEO for TEDCO, the economic engine for Maryland's technology- and life science-based startups, and Strategic Advisor for Hunter Lewis, LLC, an investment management advisory firm.
Troy founded the management consulting firm LeMaile-Stovall, LLC and co-founded GulfSouth Capital where he was the first President and CEO. As he continued his career, he has led/co-led over $2B in debt and equity offerings with over a dozen exits with double digit returns.

Troy continues to be recognized by industry peers; he selected for the Leadership Greater Washington Signature Program Class of 2019, DC Chamber Chairman's Award, Washingtonian "Tech Titan" (2022, 2024, 2025), the 2023 class for the NACD Accelerate Audit Committee Pipeline program, a 2023 Inductee into the Baltimore Dealmakers Hall of Fame, Baltimore Business Journal's Power 10 honoree (2023), BPM Global 100 (2024) and AfroNews Who's Who in Black Baltimore honoree (2024) and The Daily Record's Most Admired CEOs (2022), Influential Marylander (2025) and Power 100 (2025).
Additionally, Troy is a NACD Certified Director, serving on numerous Boards including University of Maryland School of Medicine, World Trade Center Institute, Parkway Properties, Archipelago Learning, Internet America, SchoolStatus, EpiCor Software, Harkins Builders, LIM College, Southern Methodist University Dept. of Electrical Engineering, UDC Foundation, and Landover, MD-based Zion Church, led by Sr. Pastor Keith Battle.

Prior to TEDCO, Troy served as COO at the University of the District of Columbia; Interim President of Zenith Education Group; Principal at Butler Snow Advisory Services; Executive Vice President and COO of Howard University; and Senior Vice President and CFO at Jackson State University, where he was awarded the Thurgood Marshall HBCU CFO of the Year.

Troy holds a bachelor's degree in electrical engineering from Southern Methodist University, a master's degree in computer science from Stanford University, and an MBA from Harvard University.

Rachel Jayeon Shim

General Affairs Manager
KOTRA Washington D.C.

Title: An Introduction to KOTRA

Bio: Rachel Jayeon Shim is the General Affairs Manager at KOTRA Washington D.C., where she is responsible for managing administrative affairs and supporting the office's trade and investment promotion activities.
Her work focuses on facilitating smooth operations and providing organizational support to enhance KOTRA's mission in the United States.

Abstract: This presentation introduces KOTRA's organizational structure and its mission in promoting trade and investment between Korea and the United States.
It will highlight KOTRA's North American operations and support programs for Korean companies.

DAY 1

Tae Heum Jeong, Ph.D.

Founder and Managing Partner, Adelphi Ventures

Bio: Dr. Tae Heum Jeong is a founder and Managing Partner at Adelphi Ventures, a healthcare venture capital firm and was a Managing Partner at Kensington-SV Global Innovations, a growth-stage investment firm which he co-founded in 2018. He has more than 25 years of experience as a venture capitalist and a financial executive with substantial capabilities across a range of corporate functional domains, including entrepreneurial strategy, leadership, venture capital, investment banking, and corporate development. As a venture capitalist, Dr. Jeong has been involved in the investments of over 60 companies with successful returns at KSV and Hyundai Ventures. As a science-oriented entrepreneur, he developed and executed business plans with a thorough understanding of biotechnology and pharmaceutical industry, having grown Rexahn Pharmaceuticals from inception to NASDAQ listed public company. As a seasoned financial executive at Rexahn and Clene, he raised $200M+ million through private and public offerings to develop multiple therapeutics to cure cancer and CNS disease.Dr. Jeong maintains global and senior-level relationship networks in the healthcare industries and corporate finance communities. He also served on the board of directors of Neurobo Pharmaceuticals, where he was chair of the audit committee and the board of directors of Shuttle Pharmaceuticals, Inc. Dr. Jeong received his bachelor's and master's degrees of science in chemistry from Pohang University of Science & Technology. He also holds a master of science in finance degree from Johns Hopkins University, and a doctorate of management from the University of Maryland.

Chung-Hwan Kim

Minister Counselor for Health

Bio: Mr. Kim began his public service career in 1998, and has served in various senior positions at the Ministry of Health and Welfare of Korea.
His previous roles include Inspector General (2022~2024) and Director of Population Policy, Director of Pharmaceutical Policy, and Director of Social Service Policy, etc. He also served as an Administrative Officer at the Office of the President of Korea (2018~2019). He took the greatest pride in establishing a sound and transparent distribution system for pharmaceuticals and contributing to the framework that ensures the safe use of medicines for patients.
Since June 2024, he has been serving as Minister-Counselor for Health and Welfare at the Embassy of the Republic of Korea in Washington, D.C, where he supports cooperation between Korea and the United States in the fields of health, biotechnology, and pharmaceuticals.
Mr. Kim holds an M.A. in Political Science from Södertörn University in Sweden and B.A. in Political Science and International Relations from Korea University.

Soonmahn Park, Ph.D.

President, KHIDI USA

Bio: I am currently the president of KHIDI USA in Cambridge, USA.
I have worked for KHIDI (Korea Health Industry Development Institute, a South Korean government affiliated agency) for 22 years. My prior roles with KHIDI have included research, policy development, market analysis and business planning to promote the South Korean medical devices industry.
Since March 2021, I've been helping Korean pharmaceutical, biotech, and medical device companies enter the U.S. market. My institution provides insightful and reliable information about the Korean health industry, and in our role as mediator, we can help U.S partners collaborate with South Korean companies.
Prior to KHIDI, I worked as a Software Engineer at Mediface (now INFINITT), a PACS spin-off company of the Medison Group, from 2000 to 2004. My main duties were DICOM Image Acquisition, Compression, Backup Server Development, and I led the Server Development Team at the R&D Center.
My undergraduate major was Biomedical Engineering, and my PhD was in Medical Imaging Software.

DAY 1

Susan C. Lee

Secretary of State, Maryland

Bio: Susan Lee was appointed as Maryland's 72nd Secretary of State on January 18, 2023 by Governor Wes Moore. She previously served over 20 years in the Maryland General Assembly, having been elected to the Senate in 2014 and to the House of Delegates in 2002 representing District 16. Lee, an attorney, is the first Asian American to serve as Maryland's Secretary of State, first Asian American elected to the Senate, and first Chinese American elected to the General Assembly.

During her time in the General Assembly, Lee was a leader the cutting-edge issues of cyber security, innovation, identity theft, online fraud, consumer protection, pay equity, gun safety, and championed laws to fight domestic violence, sexual assault, human trafficking, child abuse, senior abuse, and hate crimes. Lee also led efforts to promote bioscience, nanobiotechnology, telehealth, IT, and emerging technologies. Lee was the lead senate sponsor of the Maryland Equal Pay for Equal Work Act, True Freedom Act, and Anti-Exploitation Act and laws to ban ghost guns, require background checks on long gun sales, and to empower women, children, families, and all hardworking individuals.

Lee served as the Senate Majority Whip, Member of the Senate Judicial Proceedings Committee, Member of the Senate Executive Nominations Committee, Legislative Policy Committee, Joint Committee on Cybersecurity, Information Technology and Biotechnology, Governor's Council on Family Violence, Workgroup to Study Safe Harbor Policy for Youth Victims of Human Trafficking, and Workgroup to Study Child Custody Proceedings Involving Child Abuse or Domestic Violence Allegations. She also served as the Co-Chair of the Maryland Cybersecurity Council Law & Policy Subcommittee, Co-Chair of the Maryland Commission on Cyber Security, Innovation and Excellence, Co-Chair of the Maryland Identity Theft Task Force, and Co-Chair of the Nanobiotechnology Task Force, and Member of the Council on Open Data, Maryland Student Privacy Council, State Advisory Board for Juvenile Services, State Advisory Board on Administrative Hearings, Task Force to Study Bicycle Safety on Maryland Highways, and Task Force to Study Recording Deeds for Victims of Domestic Violence. Lee was the first and past Chairman of the Maryland Legislative Asian American and Pacific Islander Caucus and past President of the Women Legislators of Maryland (Women's Legislative Caucus). She also was a Member of the National Conference of State Legislatures Task Force on Immigration and Task Force on Cybersecurity and Member of the Communications, Technology & Interstate Commerce Committee, Member of the Maryland Council for New Americans, and a Presidential Elector.

Lee is the daughter of a World War II veteran of the US Navy and retired Washington Post artist. She is a product of the Montgomery County public school system, having attended Leland Junior High School, Herbert Hoover Junior High, and Winston Churchill High School. She graduated from the University of Maryland, College Park and the University of San Francisco School of Law. Having served in both the public and private sectors, Lee was an attorney with the U.S. Commission on Civil Rights, the U.S. Patent and Trademark Office, and Of Counsel with Gebhardt & Associates. She was appointed to serve on the United States Patent and Trademark Advisory Board during the Clinton Administration. Lee was a member of the Western Montgomery County Citizens Advisory Board, Jewish Foundation for Group Homes Board, Progressive Maryland, Co-Chair of the Montgomery County NAACP Multicultural Community Partnership, President of Asian Pacific American Bar Association of Greater Washington Area, and Board Member of the Asian Pacific American Institute for Congressional Studies.

Lee is an inductee of the Montgomery County Human Rights Hall of Fame and the Montgomery County Women's History Archives. She is the recipient of the Maryland Legislative Agenda for Women's Legislative Leadership Award; Women's Law Center Dorothy Beatty Memorial Award; Maryland NOW's Leadership Award; Bethesda Magazine's Women Who Inspire Award; Baltimore Sun's 25 Women to Watch Award; The Daily Record's Maryland Top 100 Women; Equality Maryland's Out for Justice Award; National Center for Children and Families' Spirit Award for Humanitarian Leadership; Baltimore Child Abuse Center's Outstanding Community Hero Award; Maryland Health Information Management Systems Award, Village of Friendship Heights Community Service Award; Progressive Maryland's Progressive Leader Award; Charles E. Smith Communities Chairman's Award for Commitment and Support of the Elderly Community; Mothers Against Drunk Driving Merit Award; Chinese American Citizens Alliance's George Frisbie Hoar Award; Korean American Senior Citizens Association MD Outstanding Senior Citizens Advocate Award and many more.

As a former state Senator and House Delegate and now as Secretary of State, I have been honored to have worked with outstanding advocates and leaders of women's, people of color, LGBTQ+, disability, faith, immigrant, civil rights, and other organizations to pass and implement landmark laws and policies that have helped uplift and empower women, children, families, and people of all backgrounds. We still must continue to work to protect and build on the significant strides made by those whose shoulders we stand on to ensure we are moving forward together to fulfil the promise of America and make this a better world for all.

Biography courtesy of the Maryland Commission for Women, 2024.

DAY 1

Michael W. Nestor, Ph.D.

Board of Director, The National Academies of Sciences, Engineering, and Medicine

Title: Beyond the Helix: Reimagining the Research Ecosystem for the Next Era of Innovation

Biography: Dr. Michael W. Nestor is Board Director of the Government-University-Industry-Philanthropy Research Roundtable (GUIPRR) at the National Academies of Sciences, Engineering, and Medicine. A recognized leader in scientific innovation and translational strategy, he has worked across research, industry, and policy to strengthen the nation's innovation ecosystem.
As Scientific Engagement Lead at Johnson & Johnson Innovation, he helped launch the Washington, DC JLABS site and supported early-stage biotechnology companies advancing breakthrough health technologies. Earlier, as Director of Neural Stem Cell Research at the Hussman Institute for Autism, his laboratory pioneered brain organoid and CRISPR-based platforms for autism research, work that led to two biotechnology spinouts, Synapstem and Autica Bio, where he now serves as Chief Scientific Officer.

Dr. Nestor has advised on science and venture strategy as a venture partner with the University of Maryland Momentum Fund and served as an AAAS Science and Technology Policy Fellow at the U.S. Department of Energy. He is the author of Anticipatory Ethics and The Use of CRISPR in Humans (Springer/Nature), an honorary member of the National Academy of Inventors, and recipient of multiple awards for leadership in translational science and innovation. He earned his Ph.D. in neuroscience from the University of Maryland School of Medicine and completed postdoctoral training at the National Institutes of Health, Rutgers University, and the New York Stem Cell Foundation.

Abstract: The traditional "triple helix" of universities, government, and industry shaped U.S. innovation for much of the twentieth century. That framework is no longer sufficient. Artificial intelligence is accelerating discovery, shortening feedback loops, and forcing a rethinking of how research is funded and coordinated. At the same time, the rise of corporate philanthropy and state-level policy initiatives is changing who participates in building the national research infrastructure. This session will explore how these forces are converging to create a more distributed and dynamic ecosystem that depends on new alignments among public investment, private giving, and translational capacity. Using regional examples, it will outline how corporate philanthropy can evolve from supplemental support to a structural catalyst that links local innovation with national science strategy.
The discussion will focus on practical models for designing an innovation architecture that reflects the realities of this new era of speed, scale, and shared responsibility.

DAY 1 - COMPANY TALK

SK Life Science

Keunyong Austin Cho, MBA.

Vice President of Commercial,
SK Life Science

Keunyong Austin Cho brings a wealth of expertise to SK Life Science as Vice President of Commercial. Based in Paramus, NJ, Austin leads both the HQ Commercial and Global Supply & Manufacturing operations for SK's commercial products, playing a pivotal role in the company's global expansion and commercial strategy. Prior to his current role, Austin served as Head of Commercial at SK Biopharmaceuticals, where he actively collaborated with partners abroad in launching and scaling products across international markets. His leadership at headquarters encompassed oversight of commercialization programs, ensuring that innovative therapies reached patients in a timely and effective manner.
Earlier in his career, Austin gained extensive experience in global pharma commercialization. Drawing from regional and headquarters roles, he developed deep capabilities in go-to-market strategy, brand strategy, and cross-functional team leadership.
Austin holds an MBA from Yonsei University and earned his undergraduate degree in Public Administration from Hankuk University of Foreign Studies, laying the foundation for his career at the intersection of public policy and global healthcare.

Samsung Bioepis

KyoungSoo Lim, MD, Ph.D.

Vice President of
Translational Medicine,
Samsung Bioepis

Title: Samsung Bioepis at an inflection point for the development of innovative new medicines

Bio: Dr. KyoungSoo Lim is a clinical pharmacologist with a strong medical background and extensive experience in early and late phase clinical development including neurology, GI, cardiovascular, metabolism and oncology. At Samsung Bioepis, he currently leads a team of non-clinical pharmacology, toxicology, DMPK and translational medicine SMEs to develop innovative new medicines.

Abstract: Samsung Bioepis is a well-known player in biosimilar space with > 10 marketed products worldwide. Now the company is preparing for its second phase of evolution, transforming into a new drug development company. The momentum is being built up from the track-record of biologics innovation and success.

DAY 2

Jongho "Philip" Won, Ph.D.

Senior Associate,
Alston & Bird, LLP

Bio: Jongho "Philip" Won holds a Ph.D. in Bioengineering and has authored more than 50 peer-reviewed articles in leading scientific journals. With seven years of experience as a medical device reviewer at the U.S. Food and Drug Administration, Dr. Won brings deep regulatory expertise to the field. Currently, he practices as a medical device attorney at Alston & Bird, LLP, providing efficient FDA regulatory strategies and guiding companies through the development of successful FDA pre-market submissions for innovative medical devices.

Brian Lee

Partner,
Alston & Bird, LLP

Bio: Brian Lee is an expert in Medicare coverage and payment issues, representing hospitals, doctors, and manufacturers as they navigate requirements and policies. Brian also provides counsel on the development and implementation of strategic initiatives in response to congressional and administrative coverage and reimbursement changes. Through Brian's work, clients have obtained new and expanded coverage, defended against payment cuts, and obtained payment increases across multiple Medicare payment systems. Brian received his JD from the University of Maryland Francis King Carey School of Law and his MPH from the Harvard T.H. Chan Schoole of Public Health.

Hyun Jong Kim

President, KAPAL CA

Bio: Mr. Hyun Jong Kim is a distinguished figure in the world of healthcare and finance, currently serving as the Chief Executive Officer of a specialized consulting firm, FLANN Inc., dedicated to assisting healthcare companies in their expansion into the U.S. healthcare market. He specializes in business development, FDA strategy, investment, and IPO readiness for biotech and healthcare companies. His illustrious career is marked by a remarkable journey through the intricate landscapes of healthcare, finance, and international collaboration, spanning both the United States and South Korea.

Lauren Hartsmith, JD, CIP

Advisor, BRANY IRB

Bio: Lauren Hartsmith is an administrative law and regulatory compliance attorney. Lauren has experience working with government, institutional, non-profit, and for-profit IRBs and HRPPs. Lauren's experience includes serving as a Policy Analyst/Senior Advisor for Public Health Education with the Office for Human Research Protections (OHRP) where she led scientific, regulatory, and legal experts to develop and revise policies and regulations. During her tenure at OHRP, she was a key analyst involved in all aspects of the revised Common Rule rulemaking process. Lauren has given over 150 trainings on research requirements such as the Common Rule, FDA regulations, and Good Clinical Practice guidelines.

Most recently, Lauren was the Director of IRB Support and Regulatory Affairs at Advarra, where she managed a variety of functions including oversight/development of IRB guidance and policies, IRB member education, IRB meeting minutes, and written reports to regulatory authorities.

Lauren holds a bachelor's degree in Geography from Vassar College and a Juris Doctorate degree from Wake Forest University School of Law. She is a member of the Maryland State Bar and a Certified IRB Professional.

DAY 2

Dr. David Kiewlich, Ph.D.

CEO, Tomorrow Biotech

Bio: Dr. David Kiewlich (Ph.D.) is a serial founder and entrepreneur in biotech. With over 30 years' experience working for industry, as well as 6 startups of his own, his background is excellently aligned with the needs and struggles of pre-commercialization startups. He founded and runs Tomorrow Biotech, which includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators, which has supported dozens of pre-seed through series B (and beyond) companies, as well as a startup and early-stage fund. With a three-year track record of 34 of 38 company successes for members of the incubator, his approach to make it easier on founders has substantially changed the concept and expectations of what incubators should look like.
In addition to Tomorrow Biotech, David is also the CSO of a cell based therapy company, focused on autoimmune disease, advisor for several biotech startups and frequent public speaker advocating for increased sustainability and greater Diversity, Equity and Inclusion (DEI) in the sciences.
BADASS Labs is more than a 501c3, non-profit biotech incubator that rents lab space to small businesses. It is a strategic ally that empowers biotech entrepreneurs to achieve their full potential. By offering a comprehensive suite of services, such as purchasing, waste management, operations and even health insurance plans for its members, BADASS Labs enables its clients to focus on their core competencies and substantially reduce their operational costs. BADASS Labs bridges the gap between research and commercialization, by facilitating novel technologies from academic, national lab or self-generated sources into viable products that can enhance the domestic supply chain and generate regional employment. While we can incubate companies at any stage, we have a particular focus on the earlier side, from Pre-Seed through Series B stages.

At BADASS Labs, you set off running with your own dedicated lab and office space, extensive equipment and unparalleled administration support, all included, for one flat fee. Our mission at BADASS Labs is to provide the maximum support for our members to achieve their scientific milestones as quickly as possible. We nurture new companies with the facilities and know-how they need to grow.
In contrast to traditional biotech accelerators, we don't require you to stay for a minimum or maximum of time, we do not have a high minimum of square footage, and we do not tie you into a high cost, high risk situation. As a 501c3, we never take equity and we never entangle IP, thus we are not incentivized to run through as many companies as possible. We are here to foster you, not push you out the door.

Every group gets a complete package consisting of:
Dedicated lab and cubicle space
Cold storge allocation (+4C, -20C, -80C and LN2)
Unlimited use of $4M of world class equipment
Unlimited use of Tissue Culture, Microbial and Chemistry areas
Gig speed dedicated Fiber Internet access
Administrative support, including Purchasing, Waste Handling, Lab Operations, Facility Management and Inspections

You will have the facilities you need, and the support you deserve, for as long as you want to stay.

Dr. Donald P. Taylor, Ph.D. MBA, CLP

Chief Ventures Officer, UC Davis Health Ventures

Bio: Donald P. Taylor, PhD, MBA, CLP, is the inaugural Chief Ventures Officer of UC Davis Health Ventures, where he leads efforts to develop and commercialize intellectual property and advance research translation in partnership with innovation, entrepreneurship, and industry engagement teams at UC Davis and UC Davis Health.
Before joining UC Davis, Dr. Taylor served as Executive Director of Licensing at The Ohio State University and as the inaugural Assistant Vice Chancellor for Commercial Translation in the Health Sciences at the University of Pittsburgh, where he was also an Associate Professor of Biomedical Informatics in the School of Medicine, Co-Director of the Center for Commercial Applications of Healthcare Data, and Executive Director of sciVelo.
A five-time life sciences entrepreneur, Dr. Taylor began his entrepreneurial career as co-founder and CEO of Net Health, which grew into one of the world's largest providers of electronic medical records (EMR) for alternative site care. He later held executive roles at Cellumen, Cernostics, Vivisimo, Strategic Healthcare Programs, and Thermo Fisher Scientific, where he played key roles in driving innovation and commercialization. These experiences extended his expertise across bioinformatics, molecular diagnostics, drug discovery tools, and global biotechnology product distribution. In addition to his entrepreneurial ventures, Dr. Taylor spent over five years in venture investments and economic development at the Pittsburgh Life Sciences Greenhouse, supporting and funding early-stage life sciences companies.
Dr. Taylor serves on the Board of Governors for Certified Licensing Professionals, Inc., and co-chairs the Intellectual Property Committee for the California Institute for Regenerative Medicine (CIRM).
In 2023, Dr. Taylor was conferred as a distinguished alumnus of the University of Pittsburgh for his pioneering work in biomedical entrepreneurship and research translation. He earned his B.S. in Information Systems from Carnegie Mellon University, his M.S. and Ph.D. in Bioengineering from the University of Pittsburgh's Swanson School of Engineering, and an MBA from Pitt's Katz Graduate School of Business. He also conducted postdoctoral research in pathology at Pitt's School of Medicine.

DAY 2

Sougato Das

President, Life Science Nation

Title: Effective Fundraising and Seed/Series A Trends

Bio: Sougato Das is the President of Life Science Nation (LSN). Sougato started his career in software development and business analysis in J&J, Merck, GSK and Sanofi. He transitioned into product management at IQVIA and Clarivate before coming to BIO in 2013, where he was the managing director of partnering, in charge of all of BIO's partnering offerings, including the International Convention. Afterwards, he exited two startups that served the pharma industry and went to become general manager at Inpart.io, makers of BIO's partnering system. He left to help his son through a rare disease, after which he joined LSN.

Abstract: Many life science companies struggle to fundraise, especially those led by first-time founders. During this session, the most common fundraising mistakes made by CEOs and their resolutions will be discussed. The lessons you learn will help you raise funds faster, more effectively and with less dilution. LSN has over a decade of experience and has helped hundreds of companies raise billions of dollars. This session brings the best of that experience to you. This session will end with a summary of seed and series A funding trends, and what that might mean for fundraising in 2025 and 2026.

COMPANY TALK

Taewon Yoon, Ph.D.

CEO, Yuhan USA Corporation

Bio: Dr. Taewon Yoon was trained as a molecular oncologist at The University of Ilinois at Chicago and did his postdoctoral training at the University of Chicago. He then continued his research at Dr. Andy Minn's lab at the University of Pennsylvania as a senior research investigator, Department of Radiation Oncology with particular interest in therapy resistance before joining Yuhan USA as a Sr BD manager. He's been leading the Yuhan USA as a CEO since 2021.

Overview: Yuhan Corporation is a South Korea-based pharmaceutical company founded in 1926 by Dr. Il-han New, an independence activist, educator, and innovative entrepreneur. Yuhan has 30+ internal research and development programs, 35+ strategic partnerships, and completed five global out-licensing deals during the past five years, resulting in a total deal size of $3.54 billion. Our most recent achievement is Lazertinib, a 3rd generation therapeutic candidate for NSCLC, which we successfully licensed out to Janssen in 2018 and was recently approved by FDA.

Byung Ha Lee, Ph.D.

CBO, Huonslab, Co., Ltd.

Title: IV-to-SC Conversion: A Strategic Approach to Expanding Patient Access with HyDiffuze™ Technology

Bio: Dr. Byung Ha Lee is the Chief Business Officer at Huonslab Co., Ltd., S. Korea, with over 15 years of experience in biopharmaceutical R&D across oncology, immuno-oncology, rare diseases, and immunology. Previously Chief Scientific Officer at NeoImmuneTech, Inc., he led translational research and biomarker strategies, and built collaborations with major pharma, KOLs, and academia. He also held leadership roles at Genexine and Samsung Biomedical Research Institute. Dr. Lee earned his Ph.D. in Biomedical Sciences from the University of Florida and completed postdoctoral training at the NIH. He has served as President of KAPAL (2021–2024) and as an expert panel member for ASCO's Educational Book.

Jeong-woo Oh, Ph.D.

Senior Research Scientist, ABLE labs, Inc.

Title: Harmony in Innovation: Advancing Organoid-Based Drug Screening through the ABLE Labs × Johns Hopkins Collaboration

Bio: Dr. Jeong-woo Oh, a Senior Research Scientist at ABLE Labs, is leading collaborative efforts with Johns Hopkins University under the GITCC-funded "NextGen OrganoidScan" project. His work focuses on developing core modules such as the light-field microscopy (LFM) system, ROS monitoring platform, organoid sorter, and automated liquid handler to advance next-generation organoid-based drug screening automation based on his research background "Lab Automation", "Organoid".

Abstract: ABLE Labs' vision for next-generation organoid-based drug screening automation, developed through the "NextGen OrganoidScan" project under the GITCC initiative. In collaboration with Johns Hopkins University, ABLE Labs is integrating advanced imaging, ROS monitoring, and automated liquid handling technologies to realize a truly connected and intelligent AUTOMATED laboratory platform.

DAY 2 - MEET WITH VENTURE CAPITALISTS

Patrick Lee, Ph.D.

Vice President,
Curie.Bio

Biotech: Patrick is part of the CSO Partner team at Curie.Bio, where he leverages his training in computational chemistry to support portfolio companies in drug discovery strategy and execution, as well as contribute to diligence efforts for evaluating new investment opportunities across diverse therapeutic areas. His experience spans the full spectrum of discovery, from hit generation to preclinical development. He contributed to two compounds that advanced into Phase I clinical trials for oncology (SGX523 and LTT462) and is a co-inventor of three additional compounds that are ready to progress to Phase II clinical trials for metabolic and renal disease (MZE001, MZE829 and MZE782). Patrick received his Ph.D. training in chemistry at UCLA and completed postdoctoral studies at Yale University under an NIH fellowship. Over his career, he has led hit generation campaigns, compound management groups, computational chemistry teams, platform initiatives, and cross-functional collaborations at SGX, Eli Lilly, Novartis, and Maze Therapeutics.

Tae Heum Jeong, Ph.D.

Founder and
Managing Partner,
Adelphi Ventures

Cross-Border: Dr. Tae Heum Jeong is a founder and Managing Partner at Adelphi Ventures, a healthcare venture capital firm and was a Managing Partner at Kensington-SV Global Innovations, a growth-stage investment firm which he co-founded in 2018. He has more than 25 years of experience as a venture capitalist and a financial executive with substantial capabilities across a range of corporate functional domains, including entrepreneurial strategy, leadership, venture capital, investment banking, and corporate development. As a venture capitalist, Dr. Jeong has been involved in the investments of over 60 companies with successful returns at KSV and Hyundai Ventures. As a science-oriented entrepreneur, he developed and executed business plans with a thorough understanding of biotechnology and pharmaceutical industry, having grown Rexahn Pharmaceuticals from inception to NASDAQ listed public company. As a seasoned financial executive at Rexahn and Clene, he raised $200M+ million through private and public offerings to develop multiple therapeutics to cure cancer and CNS disease.Dr. Jeong maintains global and senior-level relationship networks in the healthcare industries and corporate finance communities. He also served on the board of directors of Neurobo Pharmaceuticals, where he was chair of the audit committee and the board of directors of Shuttle Pharmaceuticals, Inc. Dr. Jeong received his bachelor's and master's degrees of science in chemistry from Pohang University of Science & Technology. He also holds a master of science in finance degree from Johns Hopkins University, and a doctorate of management from the University of Maryland.

Deborah Hemingway, Ph.D.

Managing Partner,
Ecphora Capital

MedTech: Dr. Deborah Hemingway is the Founder and Managing Partner of Ecphora Capital, Maryland's premiere medtech venture capital firm based in Baltimore, Maryland. Under her leadership, Ecphora Capital has deployed $18 million across 12 startups in the past two years, establishing itself as a key force in early-stage healthcare innovation. The firm holds strategic partnerships and first-look access to local premier medical research and advanced manufacturing institutions and is the first and only firm to attain the top tier of Maryland's biotechnology investment incentive tax credit program. Over the past 20 years, Dr. Hemingway has founded, funded, and served on the boards of 53 startups, bringing a wealth of expertise in medical device commercialization, strategic growth, and venture investment. Her career reflects a consistent focus on building and scaling transformative technologies at the intersection of science, healthcare, and entrepreneurship. Dr. Hemingway earned her Ph.D. in Biophysics from the University of Maryland, College Park and is widely recognized for her sharp investment instincts, operational rigor, and commitment to cultivating lasting impact in the medtech space throughout the mid-Atlantic region.

DAY 2 - MEET WITH VENTURE CAPITALISTS

Elizabeth Cho-Fertikh, Ph.D.

Managing Partner, MEDA Ventures

Angel/Seed: Elizabeth Cho-Fertikh, PhD is Co-founder and Managing Director at the healthcare investor group, MEDA Angels and as Managing Partner at MEDA Ventures. The MEDA Angels Fund has fully deployed its Fund 1 and collectively with its SPVs, has a portfolio of 23 companies, 2 exits and 0 shutdowns. Fund 2 will continue under MEDA Ventures, investing in early stage MedTech and Life Science companies and is utilizing a novel funding vehicle employing a 3rd party validated AI-predictive platform and an insurance element to protect against downside risk to life science investing while increasing the upside. She has nearly 30 years of experience in drug development & clinical trials at biotechs & startups (oncology, infectious diseases, neurodegenerative diseases), regulatory affairs, grants administration & private markets. She is also the host of the healthcare segment of the Resilient Alpha podcast, interviewing headliners, financial and investment leaders. Launched in mid-2025, the podcast has received 100K+ views, annualizing at 2 million views across multiple social media channels. The podcast is an extension of one of the largest family office networks in the US, Ivyfon. Dr. Cho-Fertikh serves on Boards/Advisory Boards of startups and can frequently be found on the speaking, judging and mentoring circuits of the startup ecosystem. She received her BA from Johns Hopkins, her MS from Georgetown University, her PhD from Thomas Jefferson School of Medicine and completed her postdoctoral fellowship at Harvard Medical School & NIH.

Seung Hyun Moon, MD

Venture Partner, Adelphi Ventures

Dr. Seung Hyun Moon is a physician and biopharma executive with 20 years of experience in commercialization, business development, medical affairs, and clinical development across rare disease, hematology / oncology, and specialty therapeutics. He partners with investors and boards to evaluate assets, structure transactions, and build companies that translate innovation into value. His current focus is identifying differentiated assets from Korean biotech companies and advancing them toward the U.S. market through venture formation or strategic partnerships. Moon holds an M.D. and M.P.A., integrating clinical / operational experience and insight with strategic expertise in life sciences.

Jung Lee, Ph.D.

Venture Partner, Adelphi Ventures

Jung Lee is a pharmaceutical/biotech executive with more than two decades of experience in R&D and has completed 60+ business transactions for partnerships, collaborations, licensing, joint ventures, and acquisitions. He is an author/inventor of fourteen publications, a book chapter, and twenty-one patents granted and filed. Jung obtained his PhD in Medicinal Chemistry from the University of Michigan and completed a post-doctoral study in Chemistry at the Massachusetts Institute of Technology.

DAY 2

Sungwon Park

Partner, Reed Smith

Title: Updates in the Digital Health World and Their Implications

Bio: Sung Park is a Partner in Reed Smith's Life Sciences Health Industry Group. Sung guides companies in developing, distributing, and marketing FDA-regulated products and, when necessary, in responding to regulatory and administrative enforcement actions by federal and state agencies. Sung also provides transactional counsel in navigating thorny issues, such as navigating through licensure issues, analyzing promotional statements, and assessing enforcement risks.Sung understands the unique business landscape of FDA-regulated products, and provides practical advice that suits the needs of the client's business. In particular, Sung has counseled companies on designing regulatory routes for pharmaceutical, digital health, and medical device products. As a bilingual attorney who has worked with many international companies, Sung understands the concerns international manufacturers and distributors have when attempting to market their products in the United States.

Kyung-Sun Kang, Ph.D.

Professor, Seoul National University, Former President of CARM

Title: Current Status of the Council of Advanced Regenerative Medicine (CARM) in Korea Cell and Gene Therapy Industry

Bio: Prof. Kang has been a full member of the Korean Academy of Science and Technology since 2011. He has published more than 300 SCI-indexed original research papers, cited over 20,000 times (h-index > 82). He founded Kangstem Biotech (listed on KOSDAQ in 2015) and Maru Therapeutics, and has served as the President and Chair of the Board of CARM since 2023.

Abstract: The Council of Advanced Regenerative Medicine (CARM) is an association of cell and gene therapy companies dedicated to fostering Korea's regenerative medicine (RM) industry and supporting its global expansion. This presentation will highlight the current status of CARM, its major initiatives, and its role in strengthening collaboration and innovation across the Korean and international RM ecosystems.

Eun Gyeong Yang, Ph.D.

Director, K-BB Center Planning Group, KIST

Title: K-BB Center: A Boston Gateway for Translational R&D and Venture Partnerships midbrain dopaminergic system

Bio: Dr. Eun Gyeong Yang leads KIST's K-BB Center Planning Group, building a global cooperation hub in Boston to accelerate R&D translation and commercialization for Korea's government-funded research institutes. A principal researcher with extensive experience in bio/health technology programs and international collaboration, she is currently spearheading K-BB's partnerships with leading institutions and investors in the Greater Boston area.

Abstract: The talk introduces K-BB Center's mission to connect Korea's top-tier research outputs with the Boston ecosystem, focusing on preclinical PoC, venture partnering, and market entry. It also highlights the 2025–2027 pipeline and the Center's plan to leverage Kendall Square as a strategic base for co-development, licensing, and startup formation.

DAY 2 KLAM

Tae-Hee Lee, Ph.D.

Postdoctoral Fellow, Radiation Oncology & Molecular Radiation Sciences, JHU

Title: Epigenetic control of topoisomerase 1 activity presents a cancer vulnerability

Bio: I am working as a postdoc at Johns Hopkins Medicine, specializing in molecular cancer biology, and conducting research on the regulatory system of DNA repair.

Abstract: DNA transactions introduce torsional constraints that pose an inherent risk to genome integrity.
While topoisomerase 1 (TOP1) activity is essential for DNA supercoil removal, the aberrant stabilization of TOP1:DNA cleavage complexes (TOP1ccs) can result in cytotoxic DNA lesions. What protects genomic hot spots of topological stress from excessive TOP1cc accumulation remains unknown. Here, we identify chromatin context as an essential means to coordinate TOP1cc resolution. Through its ability to bind poly(ADP-ribose) (PAR), the histone variant macroH2A1.1 facilitates TOP1cc repair factor recruitment and lesion turnover, thereby preventing DNA damage in response to transcription-associated topological stress. The alternatively spliced macroH2A1.2 isoform is unable to bind PAR or protect from TOP1ccs. Impaired macroH2A1.1 splicing, a frequent cancer feature, was predictive of increased sensitivity to TOP1 poisons in a pharmaco-genomic screen in breast cancer cells, and macroH2A1.1 inactivation mirrored this effect. We propose macroH2A1 alternative splicing as an epigenetic modulator of TOP.

Hyopil Kim, Ph.D.

Postdoctoral Fellow, Department of Biomedical Engineering, JHU

Title: Cell type-specific barcoding reveals the projectional architecture of the mouse midbrain dopaminergic system

Bio: I have studied molecular and neural mechanisms related to autism-spectrum disorders during PhD in Dr. Bong-Kiun Kaang's lab at Seoul National University. After my PhD, I joined Dr. Justus Kebschull's lab at Johns Hopkins University as a postdoc to learn and further develop barcoded connectomics technologies including MAPseq2 and POINTseq, expanding the utility of barcoded connectomics. I will apply my tools to address connectopathy underlying neurological disorders including autism spectrum disorders.

Abstract: Neural circuits are formed by diverse projection patterns of individual neurons. While barcoded connectomics has enabled high-throughput mapping of single-neuron projections via sequencing instead of imaging, mapping selective cell populations defined by specific gene expression is still not available. Here, I introduce POINTseq (projections of interest by sequencing), a high-throughput barcoded connectomics approach that enables cell type-specific barcoding. We applied POINTseq to midbrain dopaminergic neurons and identified over 30 connectomic cell types, vastly exceeding the known diversity of dopaminergic cell types. Furthermore, we identified stereotyped projection patterns that are implicated in specific dopaminergic functions.

Minhyeok Chang, Ph.D.

Research Associate, Neuroscience, JHU

Title: Nanotubular Network in the Brain: A New Dimension of Neuronal Connectivity beyond Synapses

Bio: Dr. Minhyeok Chang is a Research Associate in Neuroscience at Johns Hopkins School of Medicine. He earned his Ph.D. in Biophysics from POSTECH, Korea, where he was trained in advanced optical imaging of biological nanostructures. His research focuses on noncanonical intercellular communication in the brain via nanotubular network. His work was recently published in Science (October 2025) and featured in Science Magazine News, Perspective, Research Highlights and numerous presses including Le Monde. Dr. Chang has received the Paul Ehrlich Research Award from Johns Hopkins University and has been invited to present at prestigious neuroscience seminars at Yale and NYU.

Abstract: Intercellular nanotubular networks mediate material exchange, but their existence in neurons remains to be explored. We identified long, thin dendritic filopodia forming dendrite–dendrite nanotubes (DNTs) in mammalian cortex, enabling long-range calcium propagation. In situ DNTs, anatomically distinct from synaptic spines, actively transported human amyloid-β (Aβ); DNT density increased before plaque formation in the mPFC of APP/PS1 mice, suggesting that the dendrite-DNT network might play a role in Alzheimer's disease pathology. Computational models of DNT-mediated Aβ propagation recapitulated early amyloidosis, predicting selective intracellular accumulation. These findings uncover a nanotubular connectivity layer in the brain, extending neuronal communication beyond classical synapses.

DAY 2

Daeyeol Lee, Ph.D.

Bloomberg Distinguished Professor of Neuroscience, JHU

Title: Brain as a Reinforcement Learning Machine

Bio: Daeyeol Lee is a Bloomberg Distinguished Professor in the Departments of Neuroscience and of Psychological and Brain Sciences at Johns Hopkins University. After obtaining his bachelor's degree in economics from Seoul National University, he did his doctoral and postdoctoral research at the University of Illinois and the University of Minnesota, respectively. In 2020, he published a book titled the Birth of Intelligence (Oxford University Press) and in 2021, received the Samsung Ho-am Prize for Medicine. He is also a co-founder of Neurogazer Inc.

Abstract: Reinforcement learning (RL) is a process by which biological or human-made agents choose a sequence of actions to maximize desirable outcomes, and has wide-ranging applications in both neuroscience and artificial intelligence (AI). In neuroscience, it provides a framework to understand how different neural circuits and systems can be coordinated during planning, while AI research focuses on optimizing the performance of RL in specific applications. I will provide examples of RL implementation in the brain and discuss the synergy between neuroscience and AI.

Heemin Rhee, Ph.D.

President, Health Research International

Bio: I, Heemin Rhee, obtained my M.S. and Ph.D. degrees in Pharmacology from the Ohio State University Medical School in 1970 and 1973. I had worked at several medical schools in Ohio and Oklahoma for 15 years as a professor in pharmacology.

In 1990 I started work for the U.S. FDA, Center Drug Evaluation and Research as a preclinical reviewer. At the same time, I also worked for cardiovascular and diabetic researches at the U.S. NIH/NIDDK before the FDA was moved to White Oak. After my retirement from the FDA, I started to work for the International Scientific Standard, Inc., Chuncheon, Korea, as a Principal Investigator for the discovery and development of new drugs and biologicals while I was working for the Korea University, Life Science & Biotechnology Colleges, Seoul, Korea as an instructor.

Currently I am working for the Health Research International, North Potomac, Maryland, U.S.A as a President while I am working for the Korea-American Professional Association for Life Science (KAPAL) as a senior advisor. At the same time I am also serving for the Global Pharmaceutical Key Opinion Leader for Korean Health Industry Development Institute (KHIDI), Seoul, Korea.

CONFERENCE ORGANIZERS

KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

2025 9TH ANNUAL CONFERENCE



KAPAL Headquarter Committee

Jihoon Park
President

Han-sol Park
Vice President

Eunjung Choi
Admin Dir.

Byung Ha Lee
Exec. Dir.

Sang Tae Park
Exec. Dir.

Suntae Kim
IT Dir.

Young O Hahm
BD Dir.

Kwan-Ho Chung
General Dir.

Eunkyung An
Exec. Dir.

Juny Kim
Public Affairs Dir.

Woosub Lee
General Dir.

Bumrae Cho
Program Dir.

Seungwook Shin
Public Affairs Dir.

Youngmi Ji
Program Dir.

Sung Park
Program Dir.

Senior Advisors

Heemin Rhee

Hae-Young Ahn

Luke YS Oh

Jeong Kuen Song

Tae Heum Jeong

KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

KAPAL California Committee

Hyun Jong Kim
President

Mike Lee
Exec. Dir.

James Y. Lee
Program Dir.

Yong Seok Choi
General Dir.

Heejoon Um
General Dir.

Justin Lee
General Dir.

Senior Advisor

Stanford Jhee

KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

ADVERTISEMENT

KAPAL
Korean-American Professional Association in Life Sciences
한미생명과학인협회

2025 9TH ANNUAL CONFERENCE

MEDICAL KOREA
Where your days begin again

MEDICAL KOREA

WHERE YOUR DAYS BEGIN AGAIN

Ministry of Health and Welfare

KHIDI Korea Health Industry Development Institute

KPBMA

www.kpbma.or.kr/eng global@kpbma.or.kr

80TH ANNIVERSARY

About KPBMA

The **K**orea **P**harmaceutical and **B**io-Pharma **M**anufacturers **A**ssociation represents the Korean pharmaceutical and biotech industry, established in 1945 for the purpose of improving national healthcare through the sustainable development of the pharmaceutical industry. Membership extends beyond Korean pharmaceutical companies to encompass biotech firms specializing in digital therapeutics and artificial intelligence, as well as multinational pharmaceuticals.

Organization



Members

(September, 2025)

KPBMA Members	296
Pharmaceuticals	174
Bio Ventures	62
AI/Digital Healthcare	24
Multinational Pharmaceuticals	21
Service providers, etc	15

Main Activities

- **Acting as a liaison** between government and industry to foster sustainable growth
- **Establishing open innovation platforms** to promote joint research and investment (K-SPACE, KIMCo)
- **Accelerating AI-driven drug discovery** through the AIDD (AI Institute for Drug Discovery)
- **Operating full life-cycle training programs** to nurture professionals
- **Publish reports** on pharmaceutical production data, regulatory policy trends and market insights
- **Support ISO37001 certification** and **operate fair compliance codes**

Global Projects

- **Promoting open innovation** through participation in major global exhibitions and operating academia-industry-research programs
- **Creating business opportunities** through organizing public-private joint delegation programs
- **Providing information** on global market trends and regulatory issues
- **Strengthening global networks** by holding exchange events and arranging 1:1 business meetings

2025 KAPAL 9th Annual Conference

The Life Sciences Health Industry Group at Reed Smith is proud to sponsor the **2025 Korean-American Professional Association in Life Sciences 9th Annual Conference**. Our team advises companies across the healthcare and life sciences ecosystem, helping them manage the full spectrum of regulatory and transactional challenges. We support clients at every stage of the product lifecycle, from pre-market strategy to post-market compliance, across drugs, medical devices, food, dietary supplements, and cosmetics. With a global perspective and deep cross-border experience, the group is well positioned to guide international manufacturers entering and operating in the U.S. market.

The KAPAL conference provides an essential platform for fostering collaboration and innovation within the life sciences community. We look forward to contributing to these discussions and advancing the interests of professionals in this vital industry.

Scot Hasselman
Partner
Health Care
Regulatory and
Transactional

Carol Loepere
Partner
Health Care
Regulatory and
Transactional

Joe Metro
Senior Counsel
Drug Pricing

John Feldman
Partner
FTC and Advertising

Sung Park
Partner
FDA Regulatory
and Transactional

reedsmith.com

ReedSmith

psomagen

Your Trusted Multiomics Partner

psomagen

Your Genomics Experts

Since 2004, Psomagen (formerly Macrogen USA) has provided superior data quality and next-level technical support to our clients. Our North American researchers are able to complete multiomics projects and get actionable results, all from one service provider.

Reliable Customer Experience

Our customers at pharmaceutical, industrial, and academic institutions use Psomagen for reliable, high-quality data. We work hard to ensure your samples are treated with care, and that they produce meaningful results.

Multiomics Capabilities

Unlock a wealth of knowledge and enable discoveries with Psomagen's full portfolio of services and powerful bioinformatic capabilities that complement your genomics, proteomics, and spatial projects.

Certified Labs

Our labs are CLIA-certified and CAP-accredited. Plus, we're preferred providers for 10x Genomics, IDT, and other top-notch omics technology companies.

US-Based Operations

We have four US-based labs, plus a Rockville, MD customer service hub. Your samples never travel far!

Collaborative Approach

Our team is practically an extension of yours: resourceful, responsibe, and by your side every step of the way.

High-Quality Data

We have nearly 20 years of genomics research experience. our data exceeds manufacturer benchmarks, and we stay up-to-date on industry training and certifications.

Whole Genome | Methylation | Whole Exome | RNA | Single Cell

Olink Proteomics | Sanger Sequencing | Microarray | Spatial Biology | Clinical Trials

Psomagen, Inc. 1330 Piccard Drive Suite103, Rockville, MD 20850 *http://psomagen.com* **302-251-1007**

COREE

Global Reach, Proven Sales Power

Built-up sales network infrastructure keeps expanding globally to seamlessly render potential products blockbusting

Deeply-rooted China Network

- **$350m** Sales in FY2023
  96% Generated from China
- **110k** Clinics
  400k Pharmacies
- **1,546** Hospitals
  212 Grade 3A Hospitals
- **4,500** Infant & Mom Supplies Store in **200+** Cities

Integrated omni-channels
Covering medical institutions, e-commerce platforms and baby product stores

Backed by Hanmi's global business
Close sales connections with 30+ countries takes COREE from China to worldwide

Private traffic pool
Reached by VIP Home promotion ordering building up deep C-end sales infrastructure

Expanding Global E-commerce DTC Network

All future pipelines have immediate access to built-up sales infrastructure

Strong potential to be blockbusters in synergy with current portfolio

KOTRA 발간자료 및 경제통상협력데스크 사업 안내

KOTRA 해외시장뉴스

dream.kotra.or.kr 바로가기

KOTRA 경제통상협력데스크

KOTRA는 2021년 '경제통상협력데스크'를 신설하고 글로벌 이슈를 신속하게 수집하여 전파하는 현지 네트워크 구축 기반을 마련하였습니다.

워싱턴/브뤼셀	베이징	도쿄
美, EU의 경제·산업·통상 네트워크 구축 통한 협력 사업 발굴, 정보수집 강화	해외 시장정보 조사 및 공급망 리스크 모니터링	정치, 경제, 통상, 공급망, 신산업분야 등 한-일간 현안 모니터링

KOTRA 정기 뉴스레터 채널 무료 구독방법

(이메일 수신 또는 카카오톡 수신)

1. 이메일 수신 희망시
   - 해외 무역관(워싱턴, 브뤼셀, 베이징, 도쿄)에 직접 문의
2. 카카오톡 수신
   - 워싱턴 소식 이래 채널 활용, 그 외 세계이슈톡톡 채널 구독

KOTRA유튜브 채널(동영상 콘텐츠)

youtube.com/globalkotra



The Way of Yuhan

Yuhan Corporation, a group loved by the people and grown together with the people
For the last 90 years, the corporate culture of honesty and integrity,
and the strong beliefs in social responsibility are what made Yuhan what it is today.

Looking back on the path that we moved on and thinking of the path ahead,
Yuhan will make the leap as a global pharmaceutical company through innovative new drug development,
and by enabling healthiness and happiness for all the people in the world.

In the next 100 years, Yuhan Corporation will follow the noble spirit of our founder, Dr. New Ilhan,
and write the history of challenge and development moving forward.

Our challenge has already begun.

YUHAN

Huonslab

Huonslab, a subsidiary of Huons Global, is dedicated to advancing biologics research and development with a pioneering spirit. Central to its mission is the development of innovative drug delivery technologies such as HyDIFFUZE™ for universal antibody Sub-Q delivery. With a robust pipeline including HLB3-002, a clinical-stage leading candidate, and ongoing non-clinical development in various therapeutic areas, Huonslab exemplifies a commitment to addressing unmet needs of patients.

HyDIFFUZE™ enabling conversion of IV formulations into SC formulations

HyDIFFUZE™ platform is a highly acclaimed Huonslab proprietary technology for drug delivery based on hyaluronidase. It enables the conversion of IV biologics infusions to Sub-Q delivery. The platform uses a highly purified, differentiated rHuPH20 (recombinant human hyaluronidase PH20) developed with Huonslab process patent for manufacturing methods of the rHuPH20. It has an identical amino acid residue sequence to the native enzyme (Enhanze®) using CHO DG44 as host cell line. It possesses a purity that is 100 times greater than animal testes-derived hyaluronidases, and it is free of human serum albumin and preservatives. At high dose, it is co-formulated with a partner antibody in a single dose vial, drastically reducing the patient's burden of long-hour infusion. This technology works by breaking down hyaluronan and opening the microscopic channels between the individual collagen fibers in the interstitial connective tissues. As a result, this improves the ability of co-administered antibodies with hyaluronidase to reach their intended targets and be absorbed consistently and predictably.

Mechanism of Action (rHuPH20)



A Hyaluronan, a polysaccharides is depolymerized by rHuPH20 through hydrolysis

B Viscosity of hyaluronan is lowered, tissue permeability increased

C Dispersion and absorption of co-formulated drug enhanced

D Hyaluronan is reconstituted within 24 to 48 hours without tissue distortion

HyDIFFUZE™ & HyDIZYME™ platform

HyDIFFUZE™

Hyaluronidase DS (HLB3-002 Platform/API)

High Dose rHuPH20

with Human Serum Albumin free and Preservative free

Co-development of Sub-Q formulations
Or mix & Delivery
with any possible modalities
(mAb, bispecific Ab, ADC, and etc.)

HyDIZYME™

Hyaluronidase DP (HLB3-002 stand-alone)

Low Dose rHuPH20

with Human Serum Albumin free and Preservative free
1,500 IU (HLB3-002)

IND enabling package available
Pivotal PI: 4Q 2025
MFDS BLA : 2Q 2026

In-Vivo Biological Equivalence Confirmed

Rituximab/HyDIFFUZE(HLB3-002) vs. Rituximab/Enhanze



Differentiation

Patent granted in 2024 and 2025 (Method for producing human hyalruronidase PH20; Pharmaceutical formulation w/o serum albumin) and PCT application WW in progress

High-End Quality & Technology :
High purity > 99%
High Productivity
High Specific activity



Free from HSA & Preservative !

Regulatory Timeline (Hydizyme™, Stand-alone)

2024

- Obtained IND approval from Korea's MFDS to begin Phase1 clinical trial of HLB3-002. (Aug,2024)
- Announces issuance of Process Patent for HyDIFFUZE™ Drug Delivery Platform and MFDS IND Clearance for HLB3-002 (Aug, 2024)
- Announces Enrollment and Administration of First Patient in Phase 1 Pivotal Study for Hydizyme™ (Dec, 2024)

2025

- Achieves LPI in Phase 1 Pivotal Study for Recombinant Human Natural Hyaluronidase PH20 (May, 2025)
- Secures Formulation Patent for Recombinant Human Hyaluronidase Product, Hydizyme™ (July, 2025)
- Plans to apply for BLA approval in 2025 (Planned, 2025)

2026

Plans to receive product approval in 2026

rHuPH20: recombinant human hyaluronidase PH20; **cCHO**: Chinese Hamster Ovary; **AA**: amino acid; **LPI**: Last-patient-in; **IND**: Investigational New Drug Application; **BLA**: Biologics License Application; **PH**: Posterior head; **HAS**: human serum albumin; ; **PCT**: Patent Cooperation Treaty; **WW**: world wide

Huonslab is Actively Seeking a Revenue-generating Partnership for HyDIFFUZE™ / Hydizyme™

Scan the QR code to visit our company page.



A Novel Paradigm for the Treatment of Osteoarthritis

At Kolon TissueGene, we are developing advanced cell therapies to target various orthopedic diseases and degenerative disorders.

KOLON TISSUEGENE



- √ First-in-Class Disease Modifying OA Cell Therapy: Phase 3 asset with demonstrated clinical performance for patients with no alternative solutions
- √ Pain Control, Functional Improvement and Structural Improvement: Structure improvement was demonstrated via in vivo animal model and promising result from Phase 2 knee OA
- √ Convenient and Long-Lasting Effects: Off-the-shelf and Allogenic; Single intra-articular injection with long duration of pain relief effect demonstrated in patients up to 2 years.
- √ Novel MoA Targeting Underlying Disease Pathophysiology: Innovative CGT driving conversion of highly inflammatory OA joints to a non-inflammatory state, enabling pain reduction & structural improvement
- √ Positive Clinical Results (Safety & Efficacy): Efficacy and safety are significantly demonstrated through US Proof-of-Concept Phase 2 study

FDA

Knee OA

Phase3 Ongoing
Expected FDABLA Submission in2027 1H

FDA

Hip OA

Phase 2 Ready

FDA

DDD

Phase 1 Ready

DiscDegenerative Disease
Promising in vivo results

For more information, please visit the Kolon TissueGene website at https://www.tissuegene.com/en_US

ABLE Labs

Liquid Handling Robot designed for precision and efficiency

CEO: Sang Shin (https://www.linkedin.com/in/piashin) ABLE Labs is a startup that develops experimental automation robots that reduce manual labor in bio experiments. We minimize researchers wasted time and allow them to focus on their research through liquid handling robots optimized for their customers' processes. ABLE Labs aims to increase reproducibility and productivity of experiments through experimental automation robots, and based on this, become the world's best data-based, robotics-based laboratory automation company.

Flagship Products

- **NOTABLE:**
  Compact liquid handler robot with modular add-ons and user-friendly UI
  (CV < 4%, $25K~)
- **SUITABLE:**

High-performance robot for complex workflows (NGS, ELISA) with customizable features
(CV < 3%, $80K~)

- **Lab Automation:**
  We provide automation workflow, hardware, and software solutions optimized for your application.

End-to-End HTS Workflow

1.Plate Handling
Storage, de-lidding, sealing, peeling

2.Liquid Handling
Bulk dispensing, precise pipetting, non-contact transfer

3.Incubation
Controlled CO_2 environment for cell growth

4.Assay Execution
Automated reagent addition and treatment steps

5.Data Readout
Microplate reading, result confirmation, audit-ready logging

6.Automation Backbone
Robotic integration for seamless workflow

- **Plate Sealer**
- **Dispenser**
- **Microplate Reader**
- **Non Contact Liquid Handler**
- **Plate Peeler**

- **CO_2 Incubator**
- **Plate Hotel**
- **Liquid Handler**
- **Robot Arm**



- Lab Automation Page
- LinkedIn

Contact
growth@ablelabsinc.com

Ligachembio
X
KAPAL

LCB
LigaChemBio

Recruit LigaChemBio

리가켐바이오사이언스에서 미래를 함께할 글로벌 인재를 찾고 있습니다

KAPAL 인재분들의 많은 지원을 바랍니다

채용포지션

ADC센터 Project Leader
Innovation / New Modality 센터 Bio 연구원
Innovation / New Modality 센터 Chemistry 연구원
신약연구소 Translational Research 연구원
개발본부 Translational Research 센터장 : Head of Translational Research Center
중개의약팀 : Teams leader & members of Translational Medicine Team
비임상약리팀 : Team leader & members of Non-Clinical Pharmacology Team

Compensation

단독 사용가능한 아파트 및 오피스텔 제공, 항공료, 이사비 등 국내 복귀 비용 지원
자녀 학자금 지원
장기근속/우수성과 스톡옵션 제도 운영, 국내 최고수준의 기술이전 포상제도 운영
국내·외 학회참석, 온라인 교육, 자격증 취득 등 교육훈련비 지원
사내식당 운영 : 조·중·석식 무료 제공
경조사비 제공, 종합건강검진(본인 및 가족), 장기근속 포상, 법인콘도 이용 등

지원방법

회사 채용 홈페이지(www.ligachembio.com)
문의 : 경영기획팀 채용담당자 (oyj@ligachembio.com)

채용홈페이지 QR

FUELING INNOVATION BEYOND BORDERS
GLOBAL INVESTMENT
ACCELERATING LOCAL BREAKTHROUGHS

ADELPHI VENTURES

Visit our official website at
adelphiventures.com to learn more

SK biopharmaceuticals

SK life science

Together, we are Pioneering Innovations Transforming the Future of Central Nervous System Disorders and Cancer Care

SK Biopharmaceuticals is proud to be the first Korea-based company to independently discover, develop, and commercialize a molecule from inception to FDA-approval without partnering or out-licensing.

SK Biopharmaceuticals and SK Life Science, Inc. are part of SK Group, recognized as one of TIME's World's Best Companies of 2024.

Learn more and connect with us at **skbp.com** and **sklifescienceinc.com**